Avila A, et al. - Among 724 patients with Parkinson's disease (PD), researchers ascertained if the prescription of monoamine oxidase B inhibitors (MAOB-I), rasagiline and safinamide, contributes to the reduction of the dose of levodopa and/or dopamine agonists (DA) to minimize adverse reactions. They examined the evolution of levodopa equivalent dose (LED) and LED for DA (LED-DA) in the presence of rasagiline and safinamide. Data from 1,664 visits between 2006 and 2010 (321 patients) and 1,709 visits between 2014 and 2018 (403 patients) were analyzed to evaluate the impact of rasagiline and safinamide introduction, respectively. According to findings, the introduction of MAOB-I as part of routine clinical practice in the overall treatment of PD has not helped to lessen annual mean LED. Safinamide, however, reduces the annual mean LED-DA and might be associated with a long-term reduction in adverse dose-dependent effects.